WuXi Biologics (Cayman) Dirección

Dirección controles de criterios 2/4

El CEO de WuXi Biologics (Cayman) es Chris Chen , nombrado en Jan 2016, tiene una permanencia de 8.17 años. compensación anual total es CN¥78.67M, compuesta por 3.8% salario y 96.2% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.32% de las acciones de la empresa, por valor de MX$419.16M. La antigüedad media del equipo directivo y de la junta directiva es de 4.8 años y 6.5 años, respectivamente.

Información clave

Chris Chen

Chief Executive Officer (CEO)

CN¥78.7m

Compensación total

Porcentaje del salario del CEO	3.8%
Permanencia del CEO	8.2yrs
Participación del CEO	0.3%
Permanencia media de la dirección	4.8yrs
Promedio de permanencia en la Junta Directiva	6.5yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Chris Chen en comparación con los beneficios de WuXi Biologics (Cayman)?
Fecha	Compensación total	Salario	Ingresos de la empresa
Jun 30 2023	n/a	n/a	CN¥4b
Mar 31 2023	n/a	n/a	CN¥4b
Dec 31 2022	CN¥79m	CN¥3m	CN¥4b
Sep 30 2022	n/a	n/a	CN¥4b
Jun 30 2022	n/a	n/a	CN¥4b
Mar 31 2022	n/a	n/a	CN¥4b
Dec 31 2021	CN¥51m	CN¥3m	CN¥3b
Sep 30 2021	n/a	n/a	CN¥3b
Jun 30 2021	n/a	n/a	CN¥3b
Mar 31 2021	n/a	n/a	CN¥2b
Dec 31 2020	CN¥31m	CN¥3m	CN¥2b
Sep 30 2020	n/a	n/a	CN¥1b
Jun 30 2020	n/a	n/a	CN¥1b
Mar 31 2020	n/a	n/a	CN¥1b
Dec 31 2019	CN¥25m	CN¥3m	CN¥1b
Sep 30 2019	n/a	n/a	CN¥922m
Jun 30 2019	n/a	n/a	CN¥831m
Mar 31 2019	n/a	n/a	CN¥731m
Dec 31 2018	CN¥20m	CN¥2m	CN¥631m
Sep 30 2018	n/a	n/a	CN¥520m
Jun 30 2018	n/a	n/a	CN¥410m
Mar 31 2018	n/a	n/a	CN¥331m
Dec 31 2017	CN¥24m	CN¥2m	CN¥253m

Compensación vs. Mercado: La compensación total de Chris($USD10.93M) está por encima de la media de empresas de tamaño similar en el mercado MX ($USD2.37M).

Compensación vs. Ingresos: La compensación de Chris ha aumentado más de un 20% en el último año.

CEO

Chris Chen (50 yo)

8.2yrs

Permanencia

CN¥78,670,000

Compensación

Dr. Zhisheng Chen, also known as Chris, has been the Chief Executive Officer & Executive Director at WuXi Biologics (Cayman) Inc. since January 01, 2016 and since February 27, 2014 respectively. Dr. Chen i...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Ge Li	Founder & Chairman	10.1yrs	sin datos	sin datos
Zhisheng Chen	CEO & Executive Director	8.2yrs	CN¥78.67m	0.32% MX$ 419.2m
Weichang Zhou	President of Global Biologics Development & Operations	7.3yrs	CN¥24.98m	0.0059% MX$ 7.9m
Ming Tu	CFO & Executive VP	2.3yrs	sin datos	sin datos
Tang Shaogui	VP and Head of Global Communications	no data	sin datos	sin datos
Jijie Gu	Executive VP & Chief Scientific Officer	no data	sin datos	sin datos
Eileen Wang	IR Senior Director	no data	sin datos	sin datos
Cong Ding	VP & Head of Legal Department	no data	sin datos	sin datos
He Wang	Chief Compliance Officer	1.5yrs	sin datos	sin datos
Li Xiong	VP & Head of Global Human Resources	no data	sin datos	sin datos
Angus Scott Turner	Senior VP and Head of Global BD & Alliance Management	no data	sin datos	sin datos
Xuejian Xu	Senior VP & Chief Quality Officer	no data	sin datos	sin datos

4.8yrs

Permanencia media

56yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de 2269 N se considera experimentado (4.8 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Ge Li	Founder & Chairman	10.1yrs	sin datos	sin datos
Zhisheng Chen	CEO & Executive Director	10.1yrs	CN¥78.67m	0.32% MX$ 419.2m
Weichang Zhou	President of Global Biologics Development & Operations	7.8yrs	CN¥24.98m	0.0059% MX$ 7.9m
Jackson Tai	Independent Non-Executive Director	less than a year	sin datos	0.00062% MX$ 822.6k
James Larrick	Member of Scientific Advisory Board	6.2yrs	sin datos	sin datos
David D. Ho	Member of Scientific Advisory Board	6.2yrs	sin datos	sin datos
Wei-Shou Hu	Member of Scientific Advisory Board	6.2yrs	sin datos	sin datos
Ram Sasisekharan	Member of Scientific Advisory Board	6.2yrs	sin datos	sin datos
William Robert Keller	Independent Non-Executive Director	6.8yrs	CN¥570.00k	0.00052% MX$ 689.9k
Yanling Cao	Non-Executive Director	7.8yrs	sin datos	sin datos
Yibing Wu	Non-Executive Director	7.8yrs	sin datos	sin datos
Kenneth Walton Hitchner	Independent Non-Executive Director	3.8yrs	CN¥621.00k	0.0049% MX$ 6.5m

6.5yrs

Permanencia media

58.5yo

Promedio de edad

Junta con experiencia: La junta directiva de 2269 N se considera experimentada (6.5 años de antigüedad promedio).

WuXi Biologics (Cayman) Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

WuXi Biologics (Cayman) Inc., Annual General Meeting, Jun 19, 2024

WuXi Biologics (Cayman) Inc. Announces Executive Changes, Effective March 31, 2024

Less than half of directors are independent

Wuxi Biologics (Cayman) Inc. Announces Executive Changes

WuXi Biologics (Cayman) Inc., Annual General Meeting, Jun 15, 2023

Recent updates

WuXi Biologics (Cayman) Inc. (SEHK:2269) completed the acquisition of remaining 30% stake in WuXi Vaccines (Cayman) Inc. from Shanghai Hile Bio-Technology Co., Ltd. (SHSE:603718).

WuXi Reportedly Explores Sale of Pharma Units as US Restrictions Loom

WuXi Biologics Successfully Completes First Scale-Up of High-Productivity Bioprocessing Platform WuXiUI in 2,000L GMP Manufacturing

WuXi Biologics (Cayman) Inc. to Report First Half, 2024 Results on Aug 21, 2024

WuXi Biologics (Cayman) Inc., Annual General Meeting, Jun 19, 2024

WuXi Biologics (Cayman) Inc.(SEHK:2269) dropped from S&P Global 1200

WuXi Biologics (Cayman) Inc.(SEHK:2269) dropped from S&P International 700

WuXi Biologics (Cayman) Inc. to Report Q4, 2023 Results on Mar 26, 2024

WuXi Biologics Successfully Completes First 1,6000L Manufacturing Run in Ireland

WuXi Biologics Launches WuXia ADCC PLUS™ for the Development and Manufacturing of Afucosylated Antibodies that Elicit Enhanced ADCC Effect

WuXi Biologics Receives U.S. Patent for Proprietary Bispecific Antibody Technology Platform WuXiBody™

WuXi Biologics (Cayman) Inc. Announces Executive Changes, Effective March 31, 2024

Less than half of directors are independent

WuXi Biologics (Cayman) Inc. (SEHK:2269) commences an Equity Buyback Plan for 424,841,177 shares, representing 10% of its issued share capital, under the authorization approved on June 27, 2023.

Wuxi Biologics Successfully Implements Fully Integrated Continuous Process with Breakthrough Productivity of 6 g/L/Day At Pilot Scale

WuXi Biologics Launches New High-Productivity Bioprocessing Platform WuXiUI™ for Cost-Effective Commercial Manufacturing and Desirable Product Quality

Wuxi Biologics (Cayman) Inc. Announces Executive Changes

WuXi Biologics (Cayman) Inc. to Report First Half, 2023 Results on Aug 23, 2023

WuXi Biologics (Cayman) Inc., Annual General Meeting, Jun 15, 2023

WuXi Biologics (Cayman) Inc. Announces Demise of Ning Zhao, Non-Executive Director, Member of Remuneration Committee and Member of Environmental, Social and Governance Committee

WuXi Biologics (Cayman) Inc. Announces Board and Board Committee Changes

Investor sentiment deteriorates as stock falls 26%

Less than half of directors are independent

WuXi Biologics (Cayman) Inc. to Report Fiscal Year 2022 Results on Mar 22, 2023

Less than half of directors are independent

WuXi Biologics (Cayman) Inc. Announces Demise of Teh-Ming Walter Kwauk, Independent Non-Executive Director, the Chairman of the Audit Committee of the Company and A Member of the Nomination Committee of the Company

Wuxi Biologics (Cayman) Inc. Announces Appointments to Strategy Committee

WuXi Biologics (Cayman) Inc. (SEHK:2269) commences an Equity Buyback Plan for 425,926,547 shares, representing 10% of its issued share capital, under the authorization approved on June 10, 2022.

First half 2022 earnings released: EPS: CN¥0.61 (vs CN¥0.44 in 1H 2021)

WuXi Biologics (Cayman) Inc. Receives Regulatory Approvals for Drug Substance and Drug Product Facilities from U.S. FDA and EMA

Investor sentiment deteriorated over the past week

Less than half of directors are independent

First half 2022 earnings released: EPS: CN¥0.61 (vs CN¥0.44 in 1H 2021)

Less than half of directors are independent

WuXi Biologics (Cayman) Inc. Appoints Weichang Zhou as Member of the Strategy Committee

WuXi Biologics (Cayman) Inc. Provides Earnings Guidance for the Six Months Ended June 30, 2022

Less than half of directors are independent

CEO & Executive Director recently sold Mex$45m worth of stock

Investor sentiment improved over the past week

Less than half of directors are independent

Less than half of directors are independent

Wuxi Biologics (Cayman) Inc. Provides Unaudited Consolidated Earnings Guidance for the Ended December 31, 2021

WuXi Biologics Announces Completion of GMP Production At 24,000L Line of Its Drug Substance Facility MFG5

CEO & Executive Director recently bought Mex$102m worth of stock

Less than half of directors are independent

WuXi Biologics (Cayman) Inc. Provides Unaudited Consolidated Earnings Guidance for the Six Months Ended June 30, 2021

CEO & Executive Director recently sold Mex$88m worth of stock

WuXi Biologics (Cayman) Inc. (SEHK:2269) completed the acquisition of Biologics manufacturing facilities in Hangzhou of Pfizer Investment Co. Ltd.

Full year 2020 earnings released: EPS CN¥0.43 (vs CN¥0.27 in FY 2019)

Insider recently bought Mex$9.2m worth of stock

Full year 2020 earnings released: EPS CN¥0.43 (vs CN¥0.27 in FY 2019)

WuXi Biologics (Cayman) Inc. (SEHK:2269) agreed to acquire a 90% stake in CMAB Biopharma Inc. from CBC Group.

WuXi Biologics (Cayman) Inc. (SEHK:2269) entered into an equity agreement to acquire Biologics manufacturing facilities in Hangzhou of Pfizer Investment Co. Ltd.

Exelixis, Inc. Enters into License Agreement with WuXi Biologics to Support Further Expansion of its Growing Oncology Biologics Pipeline

Wuxi Biologics (Cayman) Inc. Receives Remote Pre-Approval Inspection by European Medicines Agency on MFG4 Facility

WuXi Biologics (Cayman) Inc. to Report Fiscal Year 2020 Results on Mar 23, 2021

Antengene Corporation Limited Announces Collaboration with WuXi Biologics and WuXi STA to Advance Antibody-Drug Conjugate Candidate into Clinical-stage

Executive VP recently sold Mex$275m worth of stock

Oxford BioTherapeutics Ltd Designates Second Bispecific Antibody Program Leveraging Wuxi Biologics’ Wuxibody® Platform

Oxford BioTherapeutics Designates Second Bispecific Antibody Program Leveraging WuXi Biologics’ WuXiBody® Platform

WuXi Biologics Receives GMP Certification from Brazil's ANVISA

Análisis de compensación del CEO

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media